Acquisition lays the foundation for nation-wide research, education and treatment activities for pain
treatment centers throughout Germany
LEAMINGTON, ON, May 17, 2018 /CNW/ - Aphria Inc.
("Aphria" or the "Company") ( TSX:
APH and US OTC: APHQF) today announced that its wholly-owned subsidiary Nuuvera Deutschland GmbH ("Deutschland") has acquired a 25.1% interest in
Berlin-based Schöneberg Hospital ("Schöneberg" or the "Hospital"). The acquisition
facilitates Deutschland's long-term strategy to educate German physicians and patients and advance evidence that supports the
effectiveness of medical cannabinoids. It is also the first step in Deutschland's plans to build and operate pain treatment
centers throughout Germany. The acquisition is valued at €1.2 million.
"With our partnership with Schöneberg, we are laying the groundwork to be at the forefront of medical services," said
Hendrik Knopp, Managing Director of Deutschland. "We are focused on bringing a patient-centric
approach to medical cannabis in Germany, improving awareness and education of the therapeutic
properties of medical cannabis among doctors and patients."
"The German market is among the most attractive opportunities for medical cannabis in the world, and this deal is an important
step towards furthering Deutschland's presence in the country," said Vic Neufeld , CEO of Aphria. "Like the clinic model in the Canadian market,
these pain treatment centers will serve an invaluable purpose in supporting and educating patients, physicians and the German
public in the treatment of pain, including, among other treatments, through the use of medical cannabis. We are continuing to
advance our international strategic plans with investments such as this that lay the foundation for long-term sustained growth in
every market in which we operate."
The number of German medicinal cannabis patients, currently estimated at 33,000, has grown rapidly following the passage of
"Cannabis as Medicines Act" in March 2017. Similar to the successful approach in Canada, medical cannabis in Germany is only available with a prescription.
Due to a lack of evidence-based research, German patients often struggle to find a doctor willing to prescribe cannabis. This
deal furthers Deutschland's ability to support patients with the highest level of medical care.
Deutschland is also participating in the German tender process for in-country cultivation and maintains an existing supply
agreement with one of the largest pharmaceutical distribution companies with access to over 13,000 pharmacies in Germany.
We Have a Good Thing Growing.
About Aphria
Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical
cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight allowing for the most natural growing conditions available.
Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and
returns to shareholders.
For more information, visit: aphria.ca
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations
and expectations for the financial results related to the transaction. Forward-looking statements necessarily involve known and
unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events;
marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access
sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the
medical cannabis industry in Canada generally, income tax and regulatory matters; the ability of
Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other
risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed
will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Aphria Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2018/17/c8403.html